These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10916795)

  • 1. [Absence of antiviral activity of high-dose subcutaneous beta-interferon in patients with chronic infection by genotype 1 virus C hepatitis].
    Jiménez Sáenz M; Carmona Soria I; Caunedo Alvarez A; González Vílchez J
    Med Clin (Barc); 2000 May; 114(18):717. PubMed ID: 10916795
    [No Abstract]   [Full Text] [Related]  

  • 2. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to improve virological sustained response rate by interferon therapy for patients with chronic hepatitis C.
    Izumi N
    J Gastroenterol; 2001 Apr; 36(4):281-3. PubMed ID: 11324734
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term prognosis of chronic hepatitis C--special reference to interferon therapy].
    Arakawa Y
    Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):480-5. PubMed ID: 9577579
    [No Abstract]   [Full Text] [Related]  

  • 6. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
    Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
    Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection.
    Tan FU; Cetinkaya H; Erden E; Ulkatan S; Aydin N
    Hepatogastroenterology; 2002; 49(48):1686-7. PubMed ID: 12397766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    Intern Med; 2008; 47(12):1085-90. PubMed ID: 18552464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
    Nakamura H; Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S
    Hepatogastroenterology; 2003; 50(49):222-6. PubMed ID: 12630027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.
    Schwarz KB; Mohan P; Narkewicz MR; Molleston JP; Nash SR; Hu S; Wang K; Gries JM
    J Pediatr Gastroenterol Nutr; 2006 Oct; 43(4):499-505. PubMed ID: 17033526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
    Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
    Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.
    Zampino R; Alessio L; Marrone A; Stanzione M; Boemio A; Grandone A; Minichini C; Pisaturo M; Starace M; Adinolfi LE; Sagnelli E; Coppola N
    Infez Med; 2015 Jun; 23(2):134-9. PubMed ID: 26110293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta.
    Shiratori Y; Perelson AS; Weinberger L; Imazeki F; Yokosuka O; Nakata R; Ihori M; Hirota K; Ono N; Kuroda H; Motojima T; Nishigaki M; Omata M
    J Hepatol; 2000 Aug; 33(2):313-22. PubMed ID: 10952250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 17. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of N-acetyl-cysteine on lymphomonocyte glutathione and response to interferon treatment in C-virus chronic hepatitis.
    Cimino L; Belisario MA; Intrieri M; D'Ascoli B; Sacchetti L; Salvatore F; Budillon G
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):189-93. PubMed ID: 9675657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
    Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
    Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.